Zacks Investment Research upgraded shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) from a hold rating to a buy rating in a research note released on Saturday morning. Zacks Investment Research currently has $19.00 price objective on the stock.

According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

A number of other equities research analysts have also recently commented on the stock. BTIG Research started coverage on shares of Protagonist Therapeutics in a report on Friday, July 21st. They issued a buy rating and a $36.00 price target for the company. BMO Capital Markets reduced their price objective on shares of Protagonist Therapeutics from $45.00 to $40.00 and set an outperform rating for the company in a report on Thursday, October 19th. Finally, ValuEngine upgraded shares of Protagonist Therapeutics from a sell rating to a hold rating in a report on Monday, August 28th.

Shares of Protagonist Therapeutics (PTGX) opened at $16.57 on Friday. Protagonist Therapeutics has a twelve month low of $8.00 and a twelve month high of $26.36.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Monday, November 6th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.40. The company had revenue of $8.78 million during the quarter. research analysts anticipate that Protagonist Therapeutics will post -3.66 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/protagonist-therapeutics-inc-ptgx-upgraded-to-buy-by-zacks-investment-research/1703657.html.

In other news, insider Richard S. Shames sold 2,017 shares of Protagonist Therapeutics stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $19.00, for a total transaction of $38,323.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Richard S. Shames sold 1,512 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $17.00, for a total transaction of $25,704.00. The disclosure for this sale can be found here. Insiders have sold 10,716 shares of company stock valued at $169,288 over the last quarter.

Several hedge funds and other institutional investors have recently modified their holdings of PTGX. Rhumbline Advisers acquired a new position in shares of Protagonist Therapeutics during the second quarter valued at about $114,000. Wells Fargo & Company MN lifted its position in shares of Protagonist Therapeutics by 60.8% during the third quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock valued at $169,000 after purchasing an additional 3,617 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Protagonist Therapeutics by 71.4% during the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after purchasing an additional 6,757 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Protagonist Therapeutics by 8.5% during the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Northern Capital Management LLC bought a new position in shares of Protagonist Therapeutics during the second quarter valued at about $188,000. Hedge funds and other institutional investors own 39.73% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.